Point72 Asset Management L.P. purchased a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 31,800 shares of the company’s stock, valued at approximately $1,120,000. Point72 Asset Management L.P. owned approximately 0.07% of DBV Technologies at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Marshall Wace North America L.P. bought a new stake in shares of DBV Technologies during the first quarter valued at approximately $3,566,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of DBV Technologies during the first quarter valued at approximately $3,566,000. Emory University raised its stake in shares of DBV Technologies by 7.9% in the first quarter. Emory University now owns 62,884 shares of the company’s stock valued at $2,215,000 after buying an additional 4,628 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of DBV Technologies by 21.1% in the first quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock valued at $35,098,000 after buying an additional 173,798 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its stake in shares of DBV Technologies by 14.1% in the first quarter. Sphera Funds Management LTD. now owns 90,167 shares of the company’s stock valued at $3,176,000 after buying an additional 11,109 shares in the last quarter. 48.25% of the stock is currently owned by institutional investors.
DBV Technologies S.A. (NASDAQ DBVT) traded down 0.26% during trading on Friday, hitting $45.53. 73,453 shares of the stock traded hands. DBV Technologies S.A. has a 52-week low of $31.87 and a 52-week high of $45.70. The firm has a 50-day moving average price of $38.47 and a 200 day moving average price of $35.58. The company’s market cap is $2.09 billion.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/point72-asset-management-l-p-takes-position-in-dbv-technologies-s-a-dbvt-updated-updated-updated/1180521.html.
Several analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of DBV Technologies in a research report on Thursday, July 6th. BidaskClub raised shares of DBV Technologies from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 21st. Deutsche Bank AG assumed coverage on shares of DBV Technologies in a research report on Friday, June 23rd. They issued a “buy” rating and a $46.00 price objective on the stock. ValuEngine raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $47.00 price objective on shares of DBV Technologies in a research report on Thursday, June 1st. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $48.83.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with our FREE daily email newsletter.